Compares two treatment plans for newly diagnosed acute myeloid leukemia
Compares venetoclax with CACAG against standard 3+7 chemotherapy in adults with leukemia.
Plain-language title generated from the registry record
Registry title: A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 14 to 75 with newly diagnosed acute myeloid leukemia (AML) of intermediate or high risk, not yet treated. It compares two treatment plans.
- Age
- 14 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed intermediate- or high-risk AML (not the M3 type).
Main reasons for not taking part
- Allergy or contraindication to the study drug
- Pregnant or breastfeeding women
- Liver or kidney test results above the limits set in the record
- Uncontrolled infection, organ dysfunction or severe mental illness
- Less than 6 weeks after major organ surgery
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 75 years old?
Source: NCT06928376, who can take part
Where in China
- Chinese PLA General HospitalBeijing, ChinaContact: Daihong Liu, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese PLA General Hospital
- Trial code
- NCT06928376
- Record updated
- 8 May 2026
- Original description
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).Read full original descriptionShow less
A Multicenter, Prospective, Randomized Controlled Study of the Standard "3+7" Regimen Versus Venetoclax Combined With CACAG Regimen in Newly Diagnosed Adult Patients With Intermediate- and High-risk Acute Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
Inclusion: Age 14 to 75 years (no gender limitation) Newly diagnosed with intermediate- or high-risk AML (excluding M3) Liver function: ALT and AST ≤ 2.5 times upper limit of normal; bilirubin ≤ 2 times upper limit of normal Renal function: creatinine ≤ upper limit of normal No uncontrolled infections, organ dysfunction, or severe mental illness ECOG performance status score of 0-2 and predicted survival ≥ 4 months No severe allergic constitution.
Exclusion: Allergy or contraindication to the study drug Pregnant or breastfeeding female patients Known history of alcohol or drug addiction (due to potential non-compliance) Mental illness or conditions preventing protocol compliance Less than 6 weeks after major organ surgery Liver function: ALT and AST > 2.5 times upper limit of normal; bilirubin > 2 times upper limit of normal Renal function: creatinine > upper limit of normal Deemed unsuitable for the clinical trial (poor compliance, substance abuse, etc.); -.